| 臺大學術典藏 |
2020-05-25T07:35:30Z |
Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma-A randomized phase II trial
|
Hsu C; Kuo S.-H; Hu F.-C; Cheng A.-L; Shih J.-Y; Yu C.-J; Chia-Chi Lin; Huang T.-C; Yang P.-C; Yang C.-H. |
| 臺大學術典藏 |
2020-05-25T06:52:11Z |
Phase II trial combining paclitaxel with 24-hour infusion cisplatin for chemotherapy-na?ve patients with locally advanced or metastatic breast carcinoma
|
Cheng A.-L.;Chang K.-J;Chen M.M;Bu C.-F;Yen-Shen Lu;Chao T.-Y;Huang C.-S;Hsu C; Hsu C; Huang C.-S; Chao T.-Y; YEN-SHEN LU; Bu C.-F; Chen M.M; Chang K.-J; Cheng A.-L. |
| 臺大學術典藏 |
2020-05-25T06:52:11Z |
A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil
|
Hsu C; Yang C.-H; YEN-SHEN LU; Lin C.-C; Bu C.-F; Yeh K.-H.; Yeh K.-H.;Bu C.-F;Lin C.-C;Yen-Shen Lu;Yang C.-H;Hsu C;Cheng A.-L;Hsu C.-H; Hsu C.-H; Cheng A.-L |
| 臺大學術典藏 |
2020-05-25T06:52:10Z |
Phase II study of combination doxorubicin, interferon-�\, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma
|
Cheng A.-L.;Wu C.-Y;Hsu C.-H;Yang C.-H;Yeh K.-H;Kuo S.-H;Li C.-C;Hsu C;Yen-Shen Lu; YEN-SHEN LU; Hsu C; Li C.-C; Kuo S.-H; Yeh K.-H; Yang C.-H; Hsu C.-H; Wu C.-Y; Cheng A.-L. |
| 臺大學術典藏 |
2020-05-25T06:52:10Z |
Weekly gemcitabine plus 24-h infusion of high-dose 5-fluorouracil/ leucovorin for locally advanced or metastatic carcinoma of the biliary tract
|
Cheng A.-L.;Wu C.-Y;Chen J.-S;Li C.-C;Liu H.-T;Hsu C.-H;Yen-Shen Lu;Yeh K.-H;Yang C.-H;Shen Y.-C;Hsu C; Hsu C; Shen Y.-C; Yang C.-H; Yeh K.-H; YEN-SHEN LU; Hsu C.-H; Liu H.-T; Li C.-C; Chen J.-S; Wu C.-Y; Cheng A.-L. |
| 臺大學術典藏 |
2020-05-25T06:52:09Z |
Phase II study of weekly paclitaxel and 24-hour infusion of high-dose 5-fluorouracil and leucovorin in the treatment of recurrent or metastatic gastric cancer
|
Yeh K.-H;Yen-Shen Lu;Hsu C.-H;Lin J.-F;Hsu C;Kuo S.-H;Li Jr. S;Cheng A.-L.; Yeh K.-H; YEN-SHEN LU; Hsu C.-H; Lin J.-F; Hsu C; Kuo S.-H; Li Jr. S; Cheng A.-L. |
| 臺大學術典藏 |
2020-05-25T06:52:08Z |
Phase I study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of fluorouracil/leucovorin for advanced pancreatic cancer
|
Ch'Ang H.-J;Wang C.-C;Cheng A.-L;Hsu C;Yen-Shen Lu;Chang M.-C;Lin J.-T;Wang H.-P;Shiah H.-S;Liu T.-W;Chang J.-Y;Whang-Peng J;Chen L.-T.; Ch'ang H.-J; Wang C.-C; Cheng A.-L; Hsu C; YEN-SHEN LU; Chang M.-C; Lin J.-T; Wang H.-P; Shiah H.-S; Liu T.-W; Chang J.-Y; Whang-Peng J; Chen L.-T. |
| 臺大學術典藏 |
2020-05-25T06:52:07Z |
A phase II trial of weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in patients with chemotherapy-pretreated metastatic breast cancer
|
Lin C.-C;Cheng A.-L;Hsu C.-H;Yen-Shen Lu;Hsu C;Yeh K.-H;Wu C.-Y;Huang C.-S;Yang C.-H.; Lin C.-C; Cheng A.-L; Hsu C.-H; YEN-SHEN LU; Hsu C; Yeh K.-H; Wu C.-Y; Huang C.-S; Yang C.-H. |
| 臺大學術典藏 |
2020-05-25T06:52:04Z |
Bortezomib overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells in part through the inhibition of the phosphatidylinositol 3-kinase/Akt pathway
|
Chen P.-J; Cheng A.-L.; Hsieh H.-P; YEN-SHEN LU; Hsu C.-H; Hsu C; Yeh P.-Y; Cheng A.-L.;Chen P.-J;Hsieh H.-P;Yen-Shen Lu;Hsu C.-H;Hsu C;Yeh P.-Y;Chen K.-F; Chen K.-F |
| 臺大學術典藏 |
2020-05-25T06:52:04Z |
Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma
|
Cheng A.-L.;Hsu C;Yen-Shen Lu;Wang D.-S;Fan H.-H;Yu S.-L;Liou J.-Y;Liang J.-D;Shen Y.-C;Ou D.-L; Ou D.-L; Shen Y.-C; Liang J.-D; Liou J.-Y; Yu S.-L; Fan H.-H; Wang D.-S; YEN-SHEN LU; Hsu C; Cheng A.-L. |
| 臺大學術典藏 |
2020-05-25T06:52:03Z |
Predictive and prognostic values of tau and ERCC1 in advanced breast cancer patients treated with paclitaxel and cisplatin
|
Cheng A.-L.; Lin C.-H; Chang K.-J; Kuo W.-H; Hsu C; Lee W.-C; Liau J.-Y; Huang C.-S; Shao Y.-Y;Kuo K.-T;Hu F.-C;Yen-Shen Lu;Huang C.-S;Liau J.-Y;Lee W.-C;Hsu C;Kuo W.-H;Chang K.-J;Lin C.-H;Cheng A.-L.; Shao Y.-Y; Kuo K.-T; Hu F.-C; YEN-SHEN LU |
| 臺大學術典藏 |
2020-05-25T06:51:58Z |
Efficacy, safety, and potential biomarkers of thalidomide plus metronomic chemotherapy for advanced hepatocellular carcinoma
|
Cheng A.-L.;Hsu C.-H;Shen Y.-C;Huang C.-C;Yen-Shen Lu;Hsiao C.-H;Lee K.-D;Hsu C;Lin Z.-Z;Shao Y.-Y; Shao Y.-Y; Lin Z.-Z; Hsu C; Lee K.-D; Hsiao C.-H; YEN-SHEN LU; Huang C.-C; Shen Y.-C; Hsu C.-H; Cheng A.-L. |
| 臺大學術典藏 |
2020-05-25T06:51:56Z |
The first two lines of chemotherapy for anthracycline-naive metastatic breast cancer: A comparative study of the efficacy of anthracyclines and non-anthracyclines
|
Chen W.-W;Chang D.-Y;Huang S.-M;Lin C.-H;Hsu C;Lin M.-H;Huang C.-S;Yen-Shen Lu;Cheng A.-L.; Chen W.-W; Chang D.-Y; Huang S.-M; Lin C.-H; Hsu C; Lin M.-H; Huang C.-S; YEN-SHEN LU; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-28T07:25:38Z |
A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil
|
Chih-Hung Hsu;Cheng A.-L.;Hsu C.;Yang C.-H.;Lu Y.-S.;Lin C.-C.;Bu C.-F.;Yeh K.-H.; CHIH-HUNG HSU; Cheng A.-L.; Hsu C.; Yang C.-H.; Lu Y.-S.; Lin C.-C.; Bu C.-F.; Yeh K.-H. |
| 臺大學術典藏 |
2020-04-28T07:25:37Z |
Phase II study of combination doxorubicin, interferon-α, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma
|
CHIH-HUNG HSU; Wu C.-Y.; Cheng A.-L.; Lu Y.-S.;Hsu C.;Li C.-C.;Kuo S.-H.;Yeh K.-H.;Yang C.-H.;Chih-Hung Hsu;Wu C.-Y.;Cheng A.-L.; Lu Y.-S.; Hsu C.; Li C.-C.; Kuo S.-H.; Yeh K.-H.; Yang C.-H. |
| 臺大學術典藏 |
2020-04-28T07:25:35Z |
Phase II study of weekly paclitaxel and 24-hour infusion of high-dose 5-fluorouracil and leucovorin in the treatment of recurrent or metastatic gastric cancer
|
Yeh K.-H.;Lu Y.-S.;Chih-Hung Hsu;Lin J.-F.;Hsu C.;Kuo S.-H.;Li Jr. S.;Cheng A.-L.; Yeh K.-H.; Lu Y.-S.; CHIH-HUNG HSU; Lin J.-F.; Hsu C.; Kuo S.-H.; Li Jr. S.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-28T07:25:35Z |
Phase I-II trial of weekly gemcitabine plus high-dose 5-fluorouracil and leucovorin in advanced pancreatic cancer
|
Shiah H.-S.;Cheng A.-L.;Hsu C.;Chih-Hung Hsu;Liu T.-W.;Chang J.-Y.;Jan C.-M.;Chao Y.;Yu W.-L.;Chuang T.-R.;Whang-Peng J.;Chen L.-T.; Shiah H.-S.; Cheng A.-L.; Hsu C.; CHIH-HUNG HSU; Liu T.-W.; Chang J.-Y.; Jan C.-M.; Chao Y.; Yu W.-L.; Chuang T.-R.; Whang-Peng J.; Chen L.-T. |
| 臺大學術典藏 |
2020-04-28T07:25:31Z |
Multifractionated paclitaxel and cisplatin combined with 5-fluorouracil and leucovorin in patients with metastatic or recurrent esophageal squamous cell carcinoma
|
CHIH-HUNG HSU;Cheng A.-L.;Hsu W.-L.;Tsai Y.-C.;Hsu C.;Yang C.-H.;Yeh K.-H.;Lin C.-C.; Lin C.-C.; Yeh K.-H.; Yang C.-H.; Hsu C.; Tsai Y.-C.; Hsu W.-L.; Cheng A.-L.; CHIH-HUNG HSU |
| 臺大學術典藏 |
2020-04-28T07:25:30Z |
Outcome of advanced nonsmall cell lung cancer patients receiving gemcitabine and weekly paclitaxel as first-line treatment
|
Lin C.-C.; Cheng A.-L.; Yang P.-C.; Yang C.-H.; CHIH-HUNG HSU; Yu C.-J.; Chang Y.-C.; Hsu C.; Yang C.-H.;Yang P.-C.;Cheng A.-L.;Lin C.-C.;CHIH-HUNG HSU;Yu C.-J.;Chang Y.-C.;Hsu C.;Lin Z.-Z.; Lin Z.-Z. |
| 臺大學術典藏 |
2020-04-28T07:25:28Z |
Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma
|
Lin Z.-Z.; Chen P.-J.; Shao Y.-Y.; Ding Y.-H.; Hsu C.; Cheng A.-L.; Shen Y.-C.; CHIH-HUNG HSU; Chih-Hung Hsu;Shen Y.-C.;Lin Z.-Z.;Chen P.-J.;Shao Y.-Y.;Ding Y.-H.;Hsu C.;Cheng A.-L. |
| 臺大學術典藏 |
2020-04-28T07:25:28Z |
Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma
|
Chih-Hung Hsu;Yang T.-S.;Hsu C.;Toh H.C.;Epstein R.J.;Hsiao L.-T.;Chen P.-J.;Lin Z.-Z.;Chao T.-Y.;Cheng A.-L.; CHIH-HUNG HSU; Yang T.-S.; Hsu C.; Toh H.C.; Epstein R.J.; Hsiao L.-T.; Chen P.-J.; Lin Z.-Z.; Chao T.-Y.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-28T07:25:27Z |
Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma
|
Shao Y.-Y.;Lin Z.-Z.;Hsu C.;Shen Y.-C.;Chih-Hung Hsu;Cheng A.-L.; Shao Y.-Y.; Lin Z.-Z.; Hsu C.; Shen Y.-C.; CHIH-HUNG HSU; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-28T07:25:25Z |
Inferior survival of advanced pancreatic cancer patients who received gemcitabine-based chemotherapy but did not participate in clinical trials
|
Yang S.-H. ;Kuo Y.-H. ;Tien Y.-W. ;Hsu C. ;Chih-Hung Hsu ;Kuo S.-H. ;Cheng A.-L.; Yang S.-H.; Kuo Y.-H.; Tien Y.-W.; Hsu C.; CHIH-HUNG HSU; Kuo S.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-28T07:25:25Z |
High circulating endothelial progenitor levels associated with poor survival of advanced hepatocellular carcinoma patients receiving sorafenib combined with metronomic chemotherapy
|
Shao Y.-Y. ;Lin Z.-Z. ;Chen T.-J. ;Hsu C. ;Shen Y.-C. ;Chih-Hung Hsu ;Cheng A.-L.; Shao Y.-Y.; Lin Z.-Z.; Chen T.-J.; Hsu C.; Shen Y.-C.; CHIH-HUNG HSU; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-28T07:25:14Z |
Early perfusion changes within 1 week of systemic treatment measured by dynamic contrast-enhanced MRI may predict survival in patients with advanced hepatocellular carcinoma
|
Yu C.-W.; Hsu C.-Y.; Chen B.-B.; Chen B.-B.;Hsu C.-Y.;Yu C.-W.;Liang P.-C.;Hsu C.;Chih-Hung Hsu;Cheng A.-L.;Shih T.T.-F.; Liang P.-C.; Hsu C.; CHIH-HUNG HSU; Cheng A.-L.; Shih T.T.-F. |
